Summary
HCA Healthcare, Inc. (HCA) filed its quarterly report on May 10, 2011, for the period ending March 30, 2011. A significant event during this period was the company's initial public offering (IPO) on March 15, 2011, where it raised approximately $2.5 billion in net proceeds. These proceeds were initially used to temporarily repay outstanding indebtedness under revolving credit facilities. Investors should note that HCA operates in a highly regulated and litigious healthcare industry. The company is subject to various government investigations, including a review by the Department of Justice regarding billing for implantable cardio-defibrillators (ICDs) at 87 HCA hospitals. Furthermore, changes in government healthcare programs, such as Medicare and Medicaid, represent a significant risk factor, with approximately 41% of HCA's revenues derived from these programs in 2010. Proposed changes to Medicare reimbursement rates and state budget pressures affecting Medicaid reimbursements could adversely impact future revenues.
Financial Highlights
44 data points| Revenue | $7.41B |
| Interest Expense | $533.00M |
| Net Income | $240.00M |
| EPS (Basic) | $0.54 |
| EPS (Diluted) | $0.52 |
| Shares Outstanding (Basic) | 444.20M |
| Shares Outstanding (Diluted) | 461.97M |
Key Highlights
- 1HCA Healthcare completed its initial public offering (IPO) on March 15, 2011, raising approximately $2.5 billion in net proceeds.
- 2The company used a significant portion of the IPO proceeds to temporarily repay outstanding debt.
- 3HCA is subject to ongoing government investigations, including a DOJ review of ICD billing practices across 87 hospitals.
- 4Approximately 41% of HCA's 2010 revenue was derived from Medicare and Medicaid programs, making the company vulnerable to changes in these government reimbursements.
- 5Proposed changes to Medicare reimbursement rates and state budget constraints impacting Medicaid could adversely affect future financial results.
- 6The company's disclosure controls and procedures were evaluated and found to be effective, with no material changes to internal controls over financial reporting during the period.
- 7Bylaws were amended in connection with the IPO to implement new procedures for stockholder nominations and business proposals at meetings.